| Integrated Health Ecosystem Key to Creating Better Health Outcomes and Managing Costs for Employers and Health Plans (PR Newswire) Finding the strategies that will help employers and health plans successfully adapt to the changing healthcare environment will be a focal point of a presentation given by Gordon Norman, MD, MBA, chief innovation officer for Alere, at AHIP's Institute 2010 June 9–11 in Las Vegas.  Alere is a patient-centered health management company serving large employers and health plans nationwide. us.rd.yahoo.com |
Medtronic Works to Fix Defibrillators on Battery Problem Medtronic Inc.'s Physio-Control subsidiary said Friday it recently launched a field correction effort to fix certain devices used to shock patients in cardiac arrest because it found a potential battery-power problem, and that one patient may have died as a result. online.wsj.com |
Stem Cell Competition Heating Up Michael Becker submits:According to the National Institutes of Health’s [NIH] stem cell primer, stem cells have the ability to develop into many different cell types in the body during early life and growth. In many tissues they serve as an internal repair system, dividing essentially without limit to replenish other cells. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell. For an industry segment known for both hope and hype, it is no surprise that stem cell therapies are once again making headlines. On July 30, 2010, the U.S. Food and Drug Administration [FDA] lifted the clinical hold on Geron Corporation’s (GERN) Phase I trial using its embryonic stem cell-based therapy for the treatment of patients with acute spinal cord injury. Within days of the news, shares of Geron increased more than 30%, going from $4.80 to $6.39.Complete Story » seekingalpha.com |
News Next Week for Generex May Reduce Need for Reverse Split Thomas Barnard submits:News next week at the meeting for the European Association for the Study of Diabetes in Stockholm from September 20-24, 2010, will come in the form of a paper which will show that Generex's (GNBR) buccal spray does not develop autoimmunity versus other methods of intake including needle injection. The paper's title is, " No Generation of Insulin Antibodies in Subjects with Impaired Glucose Tolerance Treated with Buccal Spray Insulin."This research suggests yet another reason for the FDA to approve a new technique for delivery of insulin through the mouth (but not the lungs) that will dramatically improve the life of diabetics in that 1) it is an easy delivery method (no painful needle pricks), and 2) that it will improve compliance.Complete Story » seekingalpha.com |
Gilead: Preventing HIV Infection With a Pill The Burrill Report submits: by Marie DaghlianJust 25 years ago, HIV-AIDS was a death sentence for anyone who contracted the disease. Although it can now be controlled by antiretroviral therapies, preventing infection has not been very effective as an estimated 2.7 million people contract the disease each year. Now, a major study has demonstrated that Gilead’s (GILD) combination pill Truvada can protect high-risk men without the disease from becoming infected with HIV. Complete Story » seekingalpha.com |